"Vitreoretinal Consultants of NY is the premier destination for retinal care in Long Island and Queens, New York. Visit our Great Neck, NY center to get top retina specialist care for macular degeneration (AMD), diabetic retinopathy, retinal tears & detachments, macular conditions, and more. Our retinal care services include diagnostic testing such as fluorescein angiography, as well as treatments such as eye injections (Avastin, Lucentis, Eylea), vitrectomy, and scleral buckle. Our retina research center also participates in many clinical trials. With locations in Nassau, Suffolk, and Queens, we are easily accessible for patients in Brooklyn, Elmhurst, Flushing, Great Neck, Hauppauge, Riverhead, Rockville Centre, and beyond."

During the past decade, Long Is. Vitreoretinal Consult conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 11 clinical trials were completed, i.e. on average, 44% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 10 clinical trials were completed. i.e. 71.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Long Is. Vitreoretinal Consult" #1 sponsor was "Hoffmann-La Roche" with 14 trials, followed by "Ionis Pharmaceuticals, Inc." with 4 trials sponsored, "Allergan" with 2 trials sponsored, "Apellis Pharmaceuticals, Inc." with 2 trials sponsored and "Bayer" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Long Is. Vitreoretinal Consult" #1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator, "National Eye Institute (NEI)" with 1 trials as a collaborator, "Novartis Pharmaceuticals" with 1 trials as a collaborator and "Regeneron Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Long Is. Vitreoretinal Consult" are "Geographic Atrophy" (6 trials), "Cytomegalovirus Retinitis" (5 trials), "Diabetic Macular Edema" (5 trials), "HIV Infections" (5 trials) and "Macular Degeneration" (3 trials). Many other conditions were trialed in "Long Is. Vitreoretinal Consult" in a lesser frequency.

Most popular intervention types in "Long Is. Vitreoretinal Consult" are "Drug" (31 trials), "Other" (8 trials), "Procedure" (5 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (11 trials), "Faricimab" (9 trials), "Aflibercept" (5 trials), "Fomivirsen sodium" (4 trials) and "Ranibizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Long Is. Vitreoretinal Consult" are 33 trials for "All" genders.

Currently, there are NaN active trials in "Long Is. Vitreoretinal Consult". undefined are not yet recruiting, 1 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Long Is. Vitreoretinal Consult, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Long Is. Vitreoretinal Consult, 2 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".